Information Provided By:
Fly News Breaks for June 4, 2018
ADAP
Jun 4, 2018 | 12:20 EDT
Leerink analyst Jonathan Chang raised his price target on Adaptimmune to $20 after the company presented a safety update from its two ongoing pilot studies with SPEAR T-cells targeting MAGE-A10 in non-small cell lung cancer, or NSCLC, and the triple tumor study in bladder, melanoma, and head & neck cancers at the ASCO meeting. He keeps an Outperform rating on Adaptimmune shares.
News For ADAP From the Last 2 Days
There are no results for your query ADAP